Structure-activity relationships of phenazines against Mycobacterium leprae were investigated by using an in vitro radiorespirometric assay. In general, activity in ascending order was observed in compounds containing no chlorine atoms, a monochlorinated phenazine nucleus, and chlorines in the para positions of both the anilino and phenyl rings. The most active compounds contained a 2,2,6,6-tetramethylpiperidine substitution at the imino nitrogen. Most of these chlorinated phenazines were considerably more active in vitro than clofazimine (B663).
Structure-activity relationships of phenazines against Mycobacterium leprae were investigated by using an in vitro radiorespirometric assay. In general, activity in ascending order was observed in compounds containing no chlorine atoms, a monochlorinated phenazine nucleus, and chlorines in the para positions of both the anilino and phenyl rings. The most active compounds contained a 2,2,6,6-tetramethylpiperidine substitution at the imino nitrogen. Most of these chlorinated phenazines were considerably more active in vitro than clofazimine (B663).
Clofazimine [3- (p-chloroanilino)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)phenazine; B663] has been used effectively in treating leprosy for over 25 years (2) . The World Health Organization recommends its use along with rifampin and dapsone in multidrug therapy of lepromatous leprosy (8) . Major advantages of B663 include low host toxicity (16) ; suppression of erythema nodosum leprosum (10, 11) , a reactive state in leprosy; and few reports of bacterial resistance. The single most common drawback of B663 is a dose-related reddish-black skin pigmentation, making its continued use objectionable to a number of patients. The most serious and dose-limiting toxicity is gastrointestinal (16) .
Recently, a series of phenazines were synthesized. They share a number of properties, including activity against clofazimine-resistant Mycobacterium smegmatis 607 and lack of uptake by body fat (and thus nonpigmentation) (13) . We studied the relative activities of these compounds against Mycobacterium leprae in vitro to determine structure-activity relationships with a view to ultimately finding a less toxic substitute for clofazimine in treating leprosy.
Unlike that for in vitro-cultivable microorganisms, drug susceptibility testing of M. leprae has, until recently, been possible only in vivo. The established mouse footpad model is expensive and time-consuming, taking 6 to 12 months to complete, requiring gram quantities of new compounds for maximum-tolerated-dose determinations, and relying upon favorable pharmacokinetics in a nonhuman system (8) . Therefore, a number of in vitro systems have been devised which involve exposure of intracellular or extracellular M. leprae to test compounds followed by measurement of some bacillary metabolic activity (6-9, 12, 15) . Although these systems appear to be useful, most are somewhat cumbersome for large-scale screening or clinical use. We therefore recently used a simpler, semiautomated, radiorespirometric assay for rapidly assessing the metabolic status of M. leprae (4) . This assay is based on the oxidation of palmitic acid to carbon dioxide and is similar to that used for rapid drug * Corresponding author. susceptibility testing of cultivable mycobacteria in the BACTEC method (14) . We describe here its use in investigating structure-activity relationships of a number of phenazine derivatives against M. leprae.
Susceptibility testing was performed by a slight modification of the method of Franzblau (4) . Briefly, footpads of M. leprae-infected, congenitally athymic nude mice were surface decontaminated by using UV irradiation, immersion in 1% iodine, and washing with 70% ethanol. Bacilli were obtained by homogenization of the footpads in Dubosalbumin medium (pH 6.5) followed by differential centrifugation. Samples were removed for contamination check on a variety of culture media (7). The remaining M. leprae suspension was held at 4°C for 2 days, during which time the culture medium was observed to confirm the absence of contamination. The suspension was then diluted in Dubosalbumin medium to a final density of 107/ml and distributed in 1-ml aliquots to 6-ml glass screw-cap vials. Phenazines were solubilized in absolute ethanol at 200 ,ug/ml with the aid of a sonicating bath and stored at 4°C until used. Dilutions were made in absolute ethanol, and 20 RI was added to the 1-ml cultures. Controls and heat-killed bacilli received 20 RI of ethanol. All groups consisted of quadruplicate samples, (228) 158 (13) 194 (45) 29 (6) 27 (5) 42 (12) 37 (3) 23 (3) 60 (23) Heat killed B663   B3884   B4017   B826   B3779 25 (9) 895 (145) 21 (6) 20 (5) 33 ( post-label addition (data not shown). However, with the exception of heat-killed cells and drug-treated cells with very low 14CO2 evolution at 1 day post-label addition, increases were proportional to the results obtained at the earlier reading. Clofazimine (B663) demonstrated relatively potent activity, as reported previously (4) . Although unhalogenated B3884 (containing a propanyldiethylamine at R3) appeared to be inactive at <1,000 ng/ml, the monochloro (B4017) and dichloro (B826) analogs were active, with the latter showing the highest activity. Changing the propanyl spacer group on the dichlorinated compound to a sec-pentyl group (B3779) had little effect; however, replacing the diethylamine moiety with a diethanolamine (B3824) resulted in a marked reduction in activity, the lowest among all of the dichloro compounds in this study. Compounds containing a pyrrolidine ring (B3793, B3849, and B3785) displayed essentially the same activity as their diethylamine analogs, with activity increasing with the degree of chlorination. Expanding the ring to a piperidine had little effect, with the dichloro analog (B3770) again appearing to be more active than the corresponding monochlorinated (B4018) phenazine. Finally, compounds containing a 2,2,6,6-tetramethylpiperidine moiety at the R3 position showed the highest activity, with no apparent difference between the monochloro (B4019) and dichloro (B3786) analogs. This is the first in vitro drug susceptibility study with M. Ieprae which yielded structure-related activity. Both chlorine substitution at R' and R2 and the nature of the R3 group affected phenazine activity. With the exception of B3824, all of the chlorinated phenazines demonstrated activity markedly superior to that of B663 at 1,000 ng/ml. In this regard, the results obtained with dichlorinated phenazines B826 and B3785 were consistent with those obtained in a previous in vitro study which used measurement of bacillary ATP as an index of drug activity (7) . The importance of the R3 substitution was readily apparent from the relatively low activity of B3824 and the high activity of B4019 and B3786. A number of the dichlorinated compounds evaluated here have also been tested against M. smegmatis 607 in vitro (13) . In general, they showed markedly superior activity compared with B663 against both clofazimine-susceptible and -resistant strains. In addition, consistent with the results in the present study, B3824 was less active than structural analogs B826 and B3779. Previous in vivo studies with M. tuberculosis revealed a potentiating effect of chlorine substitution in the peripheral anilino and phenyl rings of various phenazines (1). However, chlorine substitution alone was not sufficient to impart antituberculosis activity, and some compounds which were inactive in vivo showed in vitro activity. Indeed, compounds which do not form crystals intracellularly and do not persist in tissues (such as clofazimine does) may also have lower in vivo activity. While the efficacies of the highly active compounds in this study require in vivo confirmation, the radiorespirometric assay appears to be promising in the in vitro exploration of structure-activity relationships of antileprosy agents.
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